| Autor: |
Donald Small, Christine A. Pratilas, Keith W. Pratz, Mark J. Levis, Richard J. Jones, Michelle A. Rudek, Alice Can Ran Qin, Li Li, Hayley S. Ma, J. Kyle Bruner |
| Rok vydání: |
2023 |
| DOI: |
10.1158/0008-5472.22414571 |
| Popis: |
Figure S1: Sorafenib treatment induces phospho-ERK rebound in 32D/ITD cells. Figure S2: Further characterization of FLT3 inhibitor-mediated signaling adaptation. Figure S3: FLT3 signaling is maintained in low serum conditions. Figure S4: MEK inhibitor treatment abrogates phospho-ERK rebound. Figure S5: MEK inhibition synergizes with FLT3 inhibition to increase apoptosis in FLT3/ITD AML. Figure S6: NRAS mutant AML is sensitive to MEK inhibition but insensitive to the addition of sorafenib. Figure S7: MEK inhibition sensitizes K562 but does not sensitize PC9 or SKBR3 cells to RTK inhibition. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
